Literature DB >> 10617687

Use of constitutive G protein-coupled receptor activity for drug discovery.

G Chen1, J Way, S Armour, C Watson, K Queen, C K Jayawickreme, W J Chen, T Kenakin.   

Abstract

This article describes the behavior of transiently transfected human receptors into melanophores and the potential use of constitutive receptor activity to screen for new drug entities. Specifically, transient transfection of melanophores with different concentrations of receptor cDNA presumably leads to increased levels of receptor expression. This leads to an increased response to agonists (both maxima and potency) and, in some cases, an agonist-independent constitutive receptor activity. Transfections with increasing concentrations of the G(s) protein-coupled human calcitonin receptor type 2 (hCTR2) cDNA produced sufficient levels of constitutively activated receptor to cause elevated basal cellular responses. This was observed as a decrease in the transmittance of light through melanophores (consistent with G(s) protein activation) and increased response to human calcitonin. The receptor-mediated nature of this response was confirmed by its reversal with the hCTR2 peptide inverse agonist AC512. A collection of ligands for hCTR2 either increased or decreased constitutive hCTR2 activity, suggesting that the constitutive system was a sensitive discriminator of positive and negative ligand efficacy. Similar results were obtained with G(i)-protein-coupled receptors. Transient transfection of NPY1, NPY2, NPY4, CXCR4, and CCR5 cDNA produced increased light transmittance through melanophores (consistent with G(i)-protein activation). NPY1 cDNA produced little constitutive response on transfection, whereas maximal levels of constitutive activity ranging from 30 to 45% were observed for the other G(i)-protein-coupled receptors. Responses to agonists for these receptors increased (both maxima and potency) with increasing cDNA transfection. The receptor/G(i)-protein nature of both the constitutive and agonist-mediated responses was confirmed by elimination with pertussis toxin pretreatment. These data are discussed in terms of the theoretical aspects of constitutive receptor activity and the applicability of this approach for the general screening of G protein-coupled orphan receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617687

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay.

Authors:  C Parnot; S Bardin; S Miserey-Lenkei; D Guedin; P Corvol; E Clauser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor.

Authors:  D Ramsay; N Bevan; S Rees; G Milligan
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

3.  Mechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR.

Authors:  Baran A Ersoy; Leonardo Pardo; Sumei Zhang; Darren A Thompson; Glenn Millhauser; Cedric Govaerts; Christian Vaisse
Journal:  Nat Chem Biol       Date:  2012-06-24       Impact factor: 15.040

4.  In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?

Authors:  B B Yao; S Mukherjee; Y Fan; T R Garrison; A V Daza; G K Grayson; B A Hooker; M J Dart; J P Sullivan; M D Meyer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

5.  Histamine H3-receptor-mediated [35S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors.

Authors:  A Rouleau; X Ligneau; J Tardivel-Lacombe; S Morisset; F Gbahou; J-C Schwartz; J-M Arrang
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

6.  Analysis of agonism and inverse agonism in functional assays with constitutive activity: estimation of orthosteric ligand affinity constants for active and inactive receptor states.

Authors:  Frederick J Ehlert; Hinako Suga; Michael T Griffin
Journal:  J Pharmacol Exp Ther       Date:  2011-05-16       Impact factor: 4.030

Review 7.  New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

8.  Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein.

Authors:  Marissa I Boulware; Jason P Weick; Bryan R Becklund; Sidney P Kuo; Rachel D Groth; Paul G Mermelstein
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

9.  The third intracellular loop stabilizes the inactive state of the neuropeptide Y1 receptor.

Authors:  Melissa J S Chee; Karin Mörl; Diana Lindner; Nicole Merten; Gerald W Zamponi; Peter E Light; Annette G Beck-Sickinger; William F Colmers
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

10.  Heterotrimeric g proteins: insights into the neurobiology of mood disorders.

Authors:  Javier González-Maeso; J Javier Meana
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.